162 related articles for article (PubMed ID: 37182335)
21. [NSD3 suppresses LPS-triggered TNF-α production via promoting the dimethylation of histone H3K36 in macrophages].
Liu Z; Cheng Q; Yang L; Sun Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2018 Jun; 34(6):481-487. PubMed ID: 30236198
[TBL] [Abstract][Full Text] [Related]
22. Targeting the Nuclear Receptor-Binding SET Domain Family of Histone Lysine Methyltransferases for Cancer Therapy: Recent Progress and Perspectives.
Shrestha A; Kim N; Lee SJ; Jeon YH; Song JJ; An H; Cho SJ; Kadayat TM; Chin J
J Med Chem; 2021 Oct; 64(20):14913-14929. PubMed ID: 34488340
[TBL] [Abstract][Full Text] [Related]
23. Discovery of potent small molecule inhibitors of histone lysine methyltransferase NSDs.
Piao L; Gao Y; Xu X; Su Y; Wang YD; Zhou J; Gao Y; Fang J; Li Q; Chang S; Kong R
Eur J Med Chem; 2024 Mar; 268():116264. PubMed ID: 38412693
[TBL] [Abstract][Full Text] [Related]
24. Identification of novel class inhibitors of NSD3 methyltransferase showing a unique, bivalent binding mode in the SET domain.
Kim S; Hwang I; Kim SH; Chung HW; Ji MJ; Moon S; Park HM; Kong G; Hur W
Chem Biol Drug Des; 2023 Sep; 102(3):500-513. PubMed ID: 37072259
[TBL] [Abstract][Full Text] [Related]
25. The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer.
Bennett RL; Swaroop A; Troche C; Licht JD
Cold Spring Harb Perspect Med; 2017 Jun; 7(6):. PubMed ID: 28193767
[TBL] [Abstract][Full Text] [Related]
26. The methyltransferase NSD3 has chromatin-binding motifs, PHD5-C5HCH, that are distinct from other NSD (nuclear receptor SET domain) family members in their histone H3 recognition.
He C; Li F; Zhang J; Wu J; Shi Y
J Biol Chem; 2013 Feb; 288(7):4692-703. PubMed ID: 23269674
[TBL] [Abstract][Full Text] [Related]
27. The NSD family of protein methyltransferases in human cancer.
Vougiouklakis T; Hamamoto R; Nakamura Y; Saloura V
Epigenomics; 2015 Aug; 7(5):863-74. PubMed ID: 25942451
[TBL] [Abstract][Full Text] [Related]
28. The methyltransferase NSD3 promotes antiviral innate immunity via direct lysine methylation of IRF3.
Wang C; Wang Q; Xu X; Xie B; Zhao Y; Li N; Cao X
J Exp Med; 2017 Dec; 214(12):3597-3610. PubMed ID: 29101251
[TBL] [Abstract][Full Text] [Related]
29. Neural crest specification and migration independently require NSD3-related lysine methyltransferase activity.
Jacques-Fricke BT; Gammill LS
Mol Biol Cell; 2014 Dec; 25(25):4174-86. PubMed ID: 25318671
[TBL] [Abstract][Full Text] [Related]
30. Structural insights into the C-terminus of the histone-lysine N-methyltransferase NSD3 by small-angle X-ray scattering.
Belviso BD; Shen Y; Carrozzini B; Morishita M; di Luccio E; Caliandro R
Front Mol Biosci; 2024; 11():1191246. PubMed ID: 38516186
[TBL] [Abstract][Full Text] [Related]
31. NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism.
French CA; Rahman S; Walsh EM; Kühnle S; Grayson AR; Lemieux ME; Grunfeld N; Rubin BP; Antonescu CR; Zhang S; Venkatramani R; Dal Cin P; Howley PM
Cancer Discov; 2014 Aug; 4(8):928-41. PubMed ID: 24875858
[TBL] [Abstract][Full Text] [Related]
32. Targeting Epigenetic Changes Mediated by Members of the SMYD Family of Lysine Methyltransferases.
Padilla A; Manganaro JF; Huesgen L; Roess DA; Brown MA; Crans DC
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838987
[TBL] [Abstract][Full Text] [Related]
33. NSD3, a new SET domain-containing gene, maps to 8p12 and is amplified in human breast cancer cell lines.
Angrand PO; Apiou F; Stewart AF; Dutrillaux B; Losson R; Chambon P
Genomics; 2001 May; 74(1):79-88. PubMed ID: 11374904
[TBL] [Abstract][Full Text] [Related]
34. Structural insights into the regulation and the recognition of histone marks by the SET domain of NSD1.
Morishita M; di Luccio E
Biochem Biophys Res Commun; 2011 Aug; 412(2):214-9. PubMed ID: 21806967
[TBL] [Abstract][Full Text] [Related]
35. Histone methyltransferase SETD2: a potential tumor suppressor in solid cancers.
Chen R; Zhao WQ; Fang C; Yang X; Ji M
J Cancer; 2020; 11(11):3349-3356. PubMed ID: 32231741
[TBL] [Abstract][Full Text] [Related]
36. Understanding the Roles of the NSD Protein Methyltransferases in Head and Neck Squamous Cell Carcinoma.
Murali M; Saloura V
Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360250
[TBL] [Abstract][Full Text] [Related]
37. Profiling NSD3-dependent neural crest gene expression reveals known and novel candidate regulatory factors.
Jacques-Fricke BT; Roffers-Agarwal J; Hussein AO; Yoder KJ; Gearhart MD; Gammill LS
Dev Biol; 2021 Jul; 475():118-130. PubMed ID: 33705737
[TBL] [Abstract][Full Text] [Related]
38. Low expression of NSD1, NSD2, and NSD3 define a subset of human papillomavirus-positive oral squamous carcinomas with unfavorable prognosis.
Gameiro SF; Ghasemi F; Zeng PYF; Mundi N; Howlett CJ; Plantinga P; Barrett JW; Nichols AC; Mymryk JS
Infect Agent Cancer; 2021 Feb; 16(1):13. PubMed ID: 33588906
[TBL] [Abstract][Full Text] [Related]
39. A NSD3-targeted PROTAC suppresses NSD3 and cMyc oncogenic nodes in cancer cells.
Xu C; Meng F; Park KS; Storey AJ; Gong W; Tsai YH; Gibson E; Byrum SD; Li D; Edmondson RD; Mackintosh SG; Vedadi M; Cai L; Tackett AJ; Kaniskan HÜ; Jin J; Wang GG
Cell Chem Biol; 2022 Mar; 29(3):386-397.e9. PubMed ID: 34469831
[TBL] [Abstract][Full Text] [Related]
40. The NSD3L histone methyltransferase regulates cell cycle and cell invasion in breast cancer cells.
Zhou Z; Thomsen R; Kahns S; Nielsen AL
Biochem Biophys Res Commun; 2010 Jul; 398(3):565-70. PubMed ID: 20599755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
